Promisel Inc. announced at the JP Morgan 2026 Healthcare Conference.
Miami, Florida, January 10, 2026 - (JCN Newswire) - Promiscel, a clinical-stage cell immunotherapy company uniquely positioned in the development of potentially curative cell therapies for cancer patients, announced today that Dr. John Lee, our Chief Medical Officer, will present interim results of our lead asset, PRO CAR - 201A (a CAR T cell therapy targeting STEAP1).
This therapy is currently being conducted as the first human Phase 1 clinical trial aimed at treating metastatic castration-resistant prostate cancer (mCRPC).
The presentation will take place on January 12, 2025 (Monday) at 11:15 AM Pacific Standard Time at the Franciscan D (Ballroom Level) during the "Biotech Showcase 2026" in San Francisco, California.

Inquiry about this news
Contact Us Online



